Skip to content

Clinical trials

Phase 2 Uterine Cervical Neoplasms trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Uterine Cervical Neoplasms Phase: Phase 2 Country / region: China Clear all

121 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20112
20121
20133
20152
20172
20183
20199
20209
202120
202212
202313
202417
202519
20269

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status43
Recruiting36
Completed20
Not yet recruiting12
Active, not recruiting6
Withdrawn2
Terminated1
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Lei Li8
Sun Yat-sen University6
Cancer Institute and Hospital, Chinese Academy of Medical Sciences5
Peking Union Medical College Hospital5
Chongqing University Cancer Hospital4
Fujian Cancer Hospital4
Tianjin Medical University Cancer Institute and Hospital4
Akeso3
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.3
Jiangsu HengRui Medicine Co., Ltd.3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Uterine Cervical Neoplasms121
Endometrial Neoplasms10
Ovarian Neoplasms9
Recurrence6
Carcinoma, Non-Small-Cell Lung5
Breast Neoplasms4
Colorectal Neoplasms4
Neoplasm Metastasis3
Squamous Cell Carcinoma of Head and Neck3
Vulvar Neoplasms3

Trials

Showing 1 to 25 of 121. Each trial links to its page on Pharma Observatory.

21 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.